Latest News
Biohaven Ltd.
- Biohaven’s previously rejected rare disease drug to get fresh FDA review
- Why is Biohaven stock surging today? By Investing.com
- Biohaven Licenses IgG Degrader Portfolio to Ono Pharmaceutical for $80M Upfront, 20% Royalties
- Eyes on Asia: TCGX, Biohaven, Roche
- Ono Pharma inks $100 M agreement with Biohaven to develop and commercialise IgG degraders in Japan, South Korea, Taiwan, and ASEAN countries
- Biohaven licenses IgG degrader portfolio to Ono for Japan and select Asian markets
- Biohaven partners with Ono in $100m IgG degrader deal
- Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
- Ono to pay Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya vaccine
- Biohaven, Ono Pharma Partner to Commercialize IgG Degrader for Graves’ Disease
- Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
- Roche’s AI lab; Biohaven’s pivotal pause
Headlines from the last 30 days, linking to the original publishers. See all market news →